<DOC>
	<DOC>NCT01672762</DOC>
	<brief_summary>This study is to evaluate safety and efficacy of ASP1941 after 24 week administration to diabetic patients.</brief_summary>
	<brief_title>A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients</brief_title>
	<detailed_description>Subjects will undergo the 6-week screening period before entering the 24-week treatment period and will receive ASP1941 before breakfast during the treatment period. All subjects will be followed for 4 weeks after study treatment is discontinued.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus patients Subject is only on a diet and exercise program or has received a single antihyperglycemic agent or two antihyperglycemic agents (excluding insulin) with low dose (≤50% of the maximum dose of each recommended dosage) Subject has a HbA1c value (JDS value) between 6.5% and 9.5% and the difference of HbA1c values (JDS value) within ± 1.0% BMI 20.0 45.0 kg/m2 Type 1 Diabetes Mellitus Subject has received insulin within 12 weeks (84 days) before the study Subject has proliferative diabetic retinopathy Subject has a history of clinically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant Subject with obvious dysuria caused by a neurogenic bladder or a benign prostatic hypertrophy Subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and heart disease (NYHA Class IIIIV) within 12 weeks (84 days). Subject has heart disease, cerebral vascular disease which, in the opinion of the principal investigator or the subinvestigator, may interfere with treatment or evaluation of safety of this study. Female subject who is currently pregnant or lactating, or who is possibly pregnant Male and premenopausal Female subject who cannot use an appropriate contraception during the study Subject has a history of treatment with ASP1941 Subject has participated in another clinical study, post marketing study, or medical equipment study within 12 weeks (84 days) before providing written informed consent, or who is currently participating in any of those studies Subject has a serum creatinine value higher than upper limit of normal range Subject has a urinary microalbumin/ urinary creatinine ratio &gt; 300 mg/g in urinalysis Subject has uncontrolled severe hypertension (subject whose systolic blood pressure is &gt; 170 mmHg or diastolic blood pressure of &gt; 95 mmHg measured in a sitting position after 5 minutes of rest Subject who is judged inappropriate for enrollment into the study by the principal investigator or the subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>serum Insulin</keyword>
	<keyword>blood glucose</keyword>
	<keyword>glucose excretion</keyword>
	<keyword>hypoglycemic agents</keyword>
	<keyword>ipragliflozin</keyword>
</DOC>